Cancer Immunology, Immunotherapy

, Volume 53, Issue 12, pp 1068–1084

Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1)

  • Karl G. Kohlgraf
  • Andrew J. Gawron
  • Michiyo Higashi
  • Michelle L. VanLith
  • XiaoLing Shen
  • Thomas C. Caffrey
  • Judy M. Anderson
  • Michael A. Hollingsworth
Original Article
  • 141 Downloads

Abstract

Purpose: CD227 (MUC1), a membrane-associated glycoprotein expressed by many types of ductal epithelia, including pancreas, breast, lung, and gastrointestinal tract, is overexpressed and aberrantly glycosylated by malignant cells. We sought to define epitopes on MUC1 recognized by the different cell-mediated immune responses by an in vivo assay. Epitopes identified by this assay were evaluated for efficacy to protect mice transgenic for human MUC1 (MUC1.Tg) against MUC1-expressing tumor growth. Methods: We investigated contributions of the tandem repeat (TR) and the cytoplasmic tail (CT) of MUC1 to the MUC1-specific immunological rejection of tumor cells. MUC1 cDNA constructs, in which the TR region was deleted or the CT was truncated, were transfected into two different murine tumor cell lines (B16 and Panc02), which were used to challenge mice and evaluate immunological rejection of the tumors. We used tumor rejection in vivo to define epitopes on the TR and CT of MUC1 recognized by T cell–mediated immune responses in a preclinical murine model. Results: Our findings demonstrated that the TR and a portion of the MUC1 CT contributed to CD4+ T cell rejection of MUC1-expressing B16 tumor cells, but not rejection of MUC1-expressing Panc02 tumor cells. A separate epitope in the CT of MUC1 was necessary for CD8+ T cell rejection of Panc02 tumor cells. Based on these studies, we sought to evaluate the efficacy of immunizing mice transgenic for (and immunologically tolerant to) human MUC1 with peptides derived from the amino acid sequence of the CT of MUC1. Results showed that survival can be significantly prolonged in vaccinated MUC1.Tg mice challenged with MUC1-expressing tumor cells, without induction of autoimmune responses. Conclusions: These studies demonstrated that MUC1 peptides may be utilized as an effective anticancer immunotherapeutic, and confirmed the importance of immunogenic epitopes outside of the TR.

Keywords

Antitumor immunotherapy In vivo epitope mapping MUC1 Tumor-associated antigens Tumor immunity 

Abbreviations

aa

Amino acid

CT

Cytoplasmic tail

IFN-γ

Interferon gamma

MUC1.Tg

MUC1 transgenic mice

TR

Tandem repeat

wt

Wild-type C57BL/6 mice

References

  1. 1.
    Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magarian-Blander J, Barratt-Boyes SM (1995) MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 145:61–89PubMedGoogle Scholar
  2. 2.
    Osako M, Yonezawa S, Siddiki B, Huang J, Ho JJ, Kim YS, Sato E (1993) Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors. Cancer 71:2191–2199PubMedGoogle Scholar
  3. 3.
    Yamashita K, Yonezawa S, Tanaka S, Shirahama H, Sakoda K, Imai K, Xing PX, McKenzie IF, Hilkens J, Kim YS et al (1993) Immunohistochemical study of mucin carbohydrates and core proteins in hepatolithiasis and cholangiocarcinoma. Int J Cancer 55:82–91PubMedGoogle Scholar
  4. 4.
    Yonezawa S, Nomoto M, Matsushita S, Xing P-X, McKenzie IFC, Kim YS, Sato E (1995) Expression of MUC2 gene product in mucinous carcinoma of the breast: comparison with invasive ductal carcinoma. Acta Histochem Cytochem 28:239–246Google Scholar
  5. 5.
    Croce MV, Price MR, Segal-Eiras A (1995) Expression of monoclonal-antibody-defined antigens in fractions isolated from human breast carcinomas and patients’ serum. Cancer Immunol Immunother 40:132–137CrossRefPubMedGoogle Scholar
  6. 6.
    Domenech N, Henderson RA, Finn OJ (1995) Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 155:4766–4774PubMedGoogle Scholar
  7. 7.
    Petrarca C, Casalino B, von Mensdorff-Pouilly S, Rughetti A, Rahimi H, Scambia G, Hilgers J, Frati L, Nuti M (1999) Isolation of MUC1-primed B lymphocytes from tumour-draining lymph nodes by immunomagnetic beads. Cancer Immunol Immunother 47:272–277CrossRefPubMedGoogle Scholar
  8. 8.
    Nakamura H, Hinoda Y, Nakagawa N, Makiguchi Y, Itoh F, Endo T, Imai K (1998) Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J Gastroenterol 33:354–361CrossRefPubMedGoogle Scholar
  9. 9.
    Graham RA, Burchell JM, Beverley P, Taylor-Papadimitriou J (1996) Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int J Cancer 65:664–670CrossRefPubMedGoogle Scholar
  10. 10.
    Chien-Hung C, Wu TC (1998) Experimental vaccine strategies for cancer immunotherapy. J Biomed Sci 5:231–252CrossRefPubMedGoogle Scholar
  11. 11.
    Reddish M, MacLean GD, Koganty RR, Kan-Mitchell J, Jones V, Mitchell MS, Longenecker BM (1998) Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 76:817–823CrossRefPubMedGoogle Scholar
  12. 12.
    Heukamp LC, van Hall T, Ossendorp F, Burchell JM, Melief CJ, Taylor-Papadimitriou J, Offringa R (2002) Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope. J Immunother 25:46–56CrossRefPubMedGoogle Scholar
  13. 13.
    Graham RA, Burchell JM, Taylor-Papadimitriou J (1996) The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Cancer Immunol Immunother 42:71–80CrossRefPubMedGoogle Scholar
  14. 14.
    Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W (1999) Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93:4309–4317PubMedGoogle Scholar
  15. 15.
    Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102–3108PubMedGoogle Scholar
  16. 16.
    Heukamp LC, van der Burg SH, Drijfhout JW, Melief CJ, Taylor-Papadimitriou J, Offringa R (2001) Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)- transgenic mice. Int J Cancer 91:385–392CrossRefPubMedGoogle Scholar
  17. 17.
    Tempero RM, VanLith ML, Morikane K, Rowse GJ, Gendler SJ, Hollingsworth MA (1998) CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J Immunol 161:5500–5506PubMedGoogle Scholar
  18. 18.
    Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ (1998) Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 58:315–321PubMedGoogle Scholar
  19. 19.
    Tempero RM, Rowse GJ, Gendler SJ, Hollingsworth MA (1999) Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice. Int J Cancer 80:595–599CrossRefPubMedGoogle Scholar
  20. 20.
    Morikane K, Tempero R, Sivinski CL, Kitajima S, Gendler SJ, Hollingsworth MA (2001) Influence of organ site and tumor cell type on MUC1-specific tumor immunity. Int Immunol 13:233–240CrossRefPubMedGoogle Scholar
  21. 21.
    VanLith ML, Kohlgraf KG, Sivinski CL, Tempero RM, Hollingsworth MA (2002) MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses. Int Immunol 14:873–882CrossRefPubMedGoogle Scholar
  22. 22.
    Sivinski CL, Kohlgraf KG, VanLith ML, Morikane K, Tempero RM, Hollingsworth MA (2002) Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines. Cancer Immunol Immunother 51:327–340CrossRefPubMedGoogle Scholar
  23. 23.
    Morikane K, Tempero RM, Sivinski CL, Nomoto M, Van Lith ML, Muto T, Hollingsworth MA (1999) Organ-specific pancreatic tumor growth properties and tumor immunity. Cancer Immunol Immunother 47:287–296CrossRefPubMedGoogle Scholar
  24. 24.
    Pemberton LF, Rughetti A, Taylor-Papadimitriou J, Gendler SJ (1996) The epithelial mucin MUC1 contains at least two discrete signals specifying membrane localization in cells. J Biol Chem 271:2332–2340CrossRefPubMedGoogle Scholar
  25. 25.
    Burdick MD, Harris A, Reid CJ, Iwamura T, Hollingsworth MA (1997) Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell lines. J Biol Chem 272:24198–24202CrossRefPubMedGoogle Scholar
  26. 26.
    Gunning P, Leavitt J, Muscat G, Ng SY, Kedes L (1987) A human beta-actin expression vector system directs high-level accumulation of antisense transcripts. Proc Natl Acad Sci U S A 84:4831–4835PubMedGoogle Scholar
  27. 27.
    Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213–219CrossRefPubMedGoogle Scholar
  28. 28.
    Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163–175PubMedGoogle Scholar
  29. 29.
    Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577–580PubMedGoogle Scholar
  30. 30.
    Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J (1988) A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263:12820–12823PubMedGoogle Scholar
  31. 31.
    Siddiqui J, Abe M, Hayes D, Shani E, Yunis E, Kufe D (1988) Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc Natl Acad Sci U S A 85:2320–2323PubMedGoogle Scholar
  32. 32.
    Hareuveni M, Tsarfaty I, Zaretsky J, Kotkes P, Horev J, Zrihan S, Weiss M, Green S, Lathe R, Keydar I et al (1990) A transcribed gene, containing a variable number of tandem repeats, codes for a human epithelial tumor antigen. cDNA cloning, expression of the transfected gene and over-expression in breast cancer tissue. Eur J Biochem 189:475–486PubMedGoogle Scholar
  33. 33.
    Lai A, Gibson A, Hopkins CR, Trowbridge IS (1998) Signal-dependent trafficking of beta-amyloid precursor protein-transferrin receptor chimeras in madin-darby canine kidney cells. J Biol Chem 273:3732–3739CrossRefPubMedGoogle Scholar
  34. 34.
    Letourneur F, Klausner RD (1992) A novel di-leucine motif and a tyrosine-based motif independently mediate lysosomal targeting and endocytosis of CD3 chains. Cell 69:1143–1157CrossRefPubMedGoogle Scholar
  35. 35.
    Spicer AP, Duhig T, Chilton BS, Gendler SJ (1995) Analysis of mammalian MUC1 genes reveals potential functionally important domains. Mamm Genome 6:885–888PubMedGoogle Scholar
  36. 36.
    Zrihan-Licht S, Baruch A, Elroy-Stein O, Keydar I, Wreschner DH (1994) Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins: cytokine receptor-like molecules. FEBS Lett 356:130–136CrossRefPubMedGoogle Scholar
  37. 37.
    Pandey P, Kharbanda S, Kufe D (1995) Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res 55:4000–4003PubMedGoogle Scholar
  38. 38.
    Li Y, Ren J, Yu W, Li Q, Kuwahara H, Yin L, Carraway KL III, Kufe D (2001) The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J Biol Chem 276:35239–35242CrossRefPubMedGoogle Scholar
  39. 39.
    Li Y, Kuwahara H, Ren J, Wen G, Kufe D (2001) The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. J Biol Chem 276:6061–6064CrossRefPubMedGoogle Scholar
  40. 40.
    Schroeder JA, Thompson MC, Gardner MM, Gendler SJ (2001) Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem 276:13057–13064CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Karl G. Kohlgraf
    • 1
  • Andrew J. Gawron
    • 1
  • Michiyo Higashi
    • 1
  • Michelle L. VanLith
    • 1
  • XiaoLing Shen
    • 1
  • Thomas C. Caffrey
    • 1
  • Judy M. Anderson
    • 1
  • Michael A. Hollingsworth
    • 1
  1. 1.Eppley Institute for Research in Cancer and Allied Diseases, and the Department of Pathology and MicrobiologyUniversity of Nebraska Medical CenterOmahaUSA

Personalised recommendations